While corticosteroids are a common treatment for uveitis, effective corticosteroid-sparing therapies are necessary to maintain disease control without risking corticosteroid-related adverse events.
Noninfectious uveitis, or inflammation of the uvea, is an immune-mediated ocular disease that is frequently associated with comorbid inflammatory diseases. Patients with noninfectious intermediate, posterior, or panuveitis are estimated to have a 10-fold higher risk of blindness or low vision compared with individuals without these conditions. While corticosteroids are a common treatment for uveitis, effective corticosteroid-sparing therapies are necessary to maintain disease control without risking corticosteroid-related adverse events (AE).
Adalimumab (Humira), which is approved to treat inflammatory diseases including uveitis, was successfully used in the VISUAL I and II studies to manage uveitis. The open-label extension study, VISUAL III, the 78-week results of which were published this month in Ophthalmology, seeks to evaluate the safety and efficacy of extended treatment with adalimumab in patients who successfully completed the 2 previous trials.
The multicenter, unmasked, uncontrolled, phase 3 extension study included 371 patients in the intent-to-treat set. All patients received open-label subcutaneous adalimumab at a dose of 40 mg every other week for the duration of the study, and were allowed to start, continue, escalate, or taper corticosteroids or immunosuppressive therapies during the trial. Patients could also have 2 periocular corticosteroid injections per eye per year.
The main outcome of the study was quiescence (no active inflammatory chorioretinal or inflammatory lesions, anterior chamber cell grade of 0.5+ or less, and vitreous haze grade of 0.5+ or less in both eyes), and efficacy was also assessed (no active inflammatory lesions, anterior chamber cell grade of 0.5+ or less, vitreous haze grade 0.5+ or less, central retinal thickness, best-corrected visual acuity, and the dose of uveitis-related corticosteroids and immunomodulators). Outcomes were evaluated in both eyes at every study visit (weeks 2, 4, 8, 12, and 18; then every 12 weeks until week 78).
At study entry, 65% of patients had active uveitis, and the remaining 35% had inactive uveitis. In total, 121 (33%) were receiving immunomodulators, and 151 (41%) were using corticosteroids at baseline. During the study, 30 (8%) started using immunomodulators, and 65 (18%) started using corticosteroids. Throughout the VISUAL III study, 33 patients (9%) received local corticosteroid injections.
At week 0, 93% of patients with active uveitis were not in quiescence. By week 12, 60% achieved quiescence (which remained stable at week 78). Of those achieving quiescence, 66% were corticosteroid-free at week 78, and 23% were receiving corticosteroids at doses of 7.5 mg per day or less.
Of those who entered the trial with inactive uveitis, 85% had quiescence at week 0. By week 78, 74% experienced quiescence; 96% of the inactive uveitis group that achieved quiescence were not taking corticosteroids at week 0, and 93% were not taking corticosteroids at week 78. Only 2 patients with inactive uveitis at the study entry were receiving more than 7.5 mg of corticosteroids per day to maintain quiescence at week 78.
The mean exposure to adalimumab for all patients was 117 weeks (±70 weeks), representing 953.7 patient years (PY). In total, there were 82 AEs leading to discontinuation, 157 serious AEs (of which 36 were considered to be at least possibly related to the study drug), and 30 non-serious allergic reactions. There was a low incidence of active tuberculosis (0.1 event/100 PY), opportunistic infections (0.5 events/100 PY), serious infections (4.0 events/100 PY) and malignancies (1.3 events/100 PY).
The researchers say that their study confirms and extends the findings of early open-label trials in which treatment with adalimumab enabled substantial tapering of immunosuppresive drugs while achieving disease control, and that adalimumab was well tolerated in this study, with no new safety signals identified.
“These data suggest that adalimumab can be used for intermediate, posterior, and panuveitis as an important therapeutic option allowing patients to achieve and maintain long-term disease control with or without adjunctive corticosteroids or immunomodulators,” say the authors.
Reference
Suhler EB, Adán A, Brézin AP, et al. Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-lable study: VISUAL III. [Published online February 8, 2018.] Ophtlamology. doi: 10.1016/j.ophtha.2017.12.039.
Commercial Payer Coverage of Biosimilars: Market Share, Pricing, and Policy Shifts
December 4th 2024Researchers observe significant shifts in payer preferences for originator vs biosimilar products from 2017 to 2022, revealing growing payer interest in multiple product options, alongside the increasing market share of biosimilars, which contributed to notable reductions in both average sales prices and wholesale acquisition costs.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Aflibercept Biosimilar MYL-1701P Provides Equivalence in DME Therapy
November 27th 2024The study findings demonstrate that the aflibercept biosimilar MYL-1701P is as effective and safe as the reference aflibercept in treating diabetic macular edema (DME), offering a promising option for reducing treatment costs and improving global access to care for patients with DME.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.
Eye on Pharma: EU Aflibercept Approvals; Biosimilars Canada Campaign; Celltrion Data
November 19th 2024The European Commission grants marketing authorization to 2 aflibercept biosimilars; Biosimilars Canada launches new campaign to provide sustainable solutions to employers; Celltrion shares positive data for 2 biosimilars.